Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Blood (2024) 144 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2024-199168

Published: 2024

Journal Articles

Multi-Omic Analyses of TP53 -Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures

Jayakumar Vadakekolathu, Sarah Skuli, David J Boocock, Clare Coveney, Eruchi G Ikpo, Bofei Wang, Elena M Fenu, Hussein A. Abbas, Catherine E. Lai, Martin P Carroll, Sergio Rutella

Blood (2024) 144 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2024-201311

Published: 2024

Journal Articles

Effectiveness of Olutasidenib Versus Ivosidenib in Patients with Mutated Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia Who Are Relapsed or Refractory to Venetoclax: The 2102-HEM-101 Trial Versus a US Electronic Health Record-Based External Control Arm

Catherine E. Lai, Thomas P. Leahy, Alex Turner, Amber Thomassen, Lixia Wang, Aaron Sheppard, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 1525.

https://doi.org/10.1182/blood-2024-205601

Published: 2024

Journal Articles

Oral Decitabine-Cedazuridine: Adverse Effects and Tolerability in a Real-World, Multicenter Retrospective Study

Julia Palecki, Maya C. Rosenberg, Jason Chen, Xiaoying Zheng, Jun Han Choi, Niti Patel, Lindsay Wilde, Gina Keiffer, Catherine E. Lai, Margaret Kasner, Chetan Jeurkar

Blood (2024) 144 (Supplement 1): 6709.

https://doi.org/10.1182/blood-2024-206072

Published: 2024

Journal Articles

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

Blood (2024) 144 (Supplement 1): 736.

https://doi.org/10.1182/blood-2024-210370

Published: 2024

Journal Articles

A Novel Proteomic Profiling of the Bone Marrow Microenvironment Reveals Elevated Levels of the Chemokine CCL23 Isoforms in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 2709.

https://doi.org/10.1182/blood-2019-122121

Published: 2019

Journal Articles

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

Lacey S. Williams, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 5697.

https://doi.org/10.1182/blood-2019-122932

Published: 2019

Journal Articles

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Samah Nassereddine, MD, Kimberley Doucette, MD MSc, Vanya Aggarwal, Richard Amdur, PhD, Imad A. Tabbara, MD, Catherine E. Lai, MD

Blood (2019) 134 (Supplement_1): 2212.

https://doi.org/10.1182/blood-2019-124150

Published: 2019

Journal Articles

Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States

Adam Zrinski Albitar, BS, Neil Shah, MD, James K McCloskey, MD, Jamie L. Koprivnikar, MD, Jianhua Zhao, PhD, Chirag Desai, MS, MBA, Sucha Sudarsanam, MS, Maher Albitar, MD, Catherine E. Lai, MD

Blood (2018) 132 (Supplement 1): 1393.

https://doi.org/10.1182/blood-2018-99-117365

Published: 2018

Journal Articles

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Katherine E Lindblad, Julie Thompson, RN, Gege Gui, MS, Janet Valdez, Tatyana Worthy, Hanna Tekleab, Tom Hughes, Pharm.D., Meghali Goswami, BS, Karolyn Oetjen, MD, Dong-Yun Kim, PhD, Laura Dillon, PhD, Christin DeStefano, MD, Catherine E. Lai, MD, Christopher S. Hourigan, DPhil FACP FRCP

Blood (2018) 132 (Supplement 1): 1437.

https://doi.org/10.1182/blood-2018-99-115097

Published: 2018

Journal Articles

Increased Frequencies of PD-1+ CD8+ Marrow-Infiltrating Lymphocytes Associated with Highly Clonal T-Lymphocyte Expansions in Relapsed and Refractory AML Patients but Not Healthy Adults

Meghali Goswami, Karolyn Oetjen, MD PhD, Matthew P. Mulé, BS, Sheenu Sheela, MBBS, Hong Yuen Wong, PhD, Qingguo Liu, MD, Katherine R. Calvo, MD PhD, Catherine E. Lai, MD, Christopher S. Hourigan, MD PhD

Blood (2016) 128 (22): 1644.

https://doi.org/10.1182/blood.V128.22.1644.1644

Published: 2016

Journal Articles

Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

Matthew P. Mulé, BS, Gabriel N. Mannis, MD, Jerald P. Radich, MD, Brent L. Wood, MDPhD, Nestor R. Ramos, MD, Catherine E. Lai, MD, Michael Flanders, BA, Charalambos Andreadis, MD MSCE, Lloyd E. Damon, MD, Aaron C. Logan, MDPhD, Thomas G. Martin, MD, Christopher S. Hourigan, MDPhD

Blood (2015) 126 (23): 4350.

https://doi.org/10.1182/blood.V126.23.4350.4350

Published: 2015

Journal Articles

Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct

Robert Q. Le, MD PhD, Prathima Anandi, MD, Xin Tian, PhD, Sawa Ito, MD, Natasha A Jain, MD, Meghali Goswami, Catherine E. Lai, MD, Christopher S. Hourigan, MDPhD, Sharon Adams, Nancy F. Hensel, Austin John Barrett, MDFRCP,FRCPath, Minoo Battiwalla, MD MS

Blood (2015) 126 (23): 3212.

https://doi.org/10.1182/blood.V126.23.3212.3212

Published: 2015

Journal Articles

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

Kieron Dunleavy, MD, Catherine E. Lai, MD, Mark Roschewski, MD, Jennifer N Brudno, MD, Brigitte Widemann, MD, Stefania Pittaluga, MD PhD, Elaine S Jaffe, MD, Andrea N Lucas, RN, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Pamela Harris, MD, Diane Cole, John A Butman, MD, Richard F Little, MD, Louis M Staudt, MD, Wyndham H Wilson, MD PhD

Blood (2015) 126 (23): 472.

https://doi.org/10.1182/blood.V126.23.472.472

Published: 2015

Journal Articles

Development of Somatic NRAS Mutation Associated with Rapid Transition from Germline GATA2 Mutation Associated Myelodysplastic Syndrome to Acute Myeloid Leukemia

Yanqin Yang, MDMSc, Yubo Zhang, PhD, Jun Zhu, PhD, Catherine E. Lai, MD, Jingrong Tang, MD PhD, Lisa J. McReynolds, MD PhD, Amy P Hsu, Dennis D. Hickstein, MD, Danielle M. Townsley, MD, Steven M. Holland, MD, Katherine R. Calvo, MD, PhD, Christopher S. Hourigan, MDPhD

Blood (2015) 126 (23): 3616.

https://doi.org/10.1182/blood.V126.23.3616.3616

Published: 2015

Journal Articles

Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy

Kieron Dunleavy, MD, Stefania Pittaluga, MD, Margaret Shovlin, RN, Svetlana Pack, Seth M. Steinberg, PhD, Catherine E. Lai, MD, Cliona Grant, MD, Eric D. Hsi, MD, Louis M. Staudt, MD, PhD, Elaine S. Jaffe, MD, Wyndham H Wilson, MD, PhD

Blood (2013) 122 (21): 3029.

https://doi.org/10.1182/blood.V122.21.3029.3029

Published: 2013

NARROW

Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Multi-Omic Analyses of TP53 -Mutated Acute Myeloid Leukemia Identify Prognostic Metabolic Signatures

Effectiveness of Olutasidenib Versus Ivosidenib in Patients with Mutated Isocitrate Dehydrogenase 1 Acute Myeloid Leukemia Who Are Relapsed or Refractory to Venetoclax: The 2102-HEM-101 Trial Versus a US Electronic Health Record-Based External Control Arm

Oral Decitabine-Cedazuridine: Adverse Effects and Tolerability in a Real-World, Multicenter Retrospective Study

Efficacy and Safety of Pembrolizumab Added to Azacitidine Plus Venetoclax for Patients with Acute Myeloid Leukemia: Results from an Investigator-Initiated, Multi-Center, CTEP-Sponsored Randomized, Phase II Trial (BLAST AML-2)

A Novel Proteomic Profiling of the Bone Marrow Microenvironment Reveals Elevated Levels of the Chemokine CCL23 Isoforms in Acute Myeloid Leukemia

Donor Cell Acute Myeloid Leukemia after Transplant for Follicular Lymphoma

The Impact of Diagnosis to Treatment Interval on the Outcome of Patients with Acute Myeloid Leukemia

Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States

Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia

Increased Frequencies of PD-1+ CD8+ Marrow-Infiltrating Lymphocytes Associated with Highly Clonal T-Lymphocyte Expansions in Relapsed and Refractory AML Patients but Not Healthy Adults

Multigene MRD Assessment Improves AML Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct

Phase I Study of Dose-Adjusted-Teddi-R with Ibrutinib in Untreated and Relapsed/Refractory Primary CNS Lymphoma

Development of Somatic NRAS Mutation Associated with Rapid Transition from Germline GATA2 Mutation Associated Myelodysplastic Syndrome to Acute Myeloid Leukemia

Concurrent Expression Of MYC/BCL2 Protein In Newly Diagnosed DLBCL Is Not Associated With An Inferior Survival Following EPOCH-R Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only